| 252.95 Data as of May 20 |  +0.20 / +0.08%Today’s Change | 154.90 Today|||52-Week Range 257.35 | +26.47% Year-to-Date |
| Good News for Roche's Tarceva - Analyst Blog May 16 / Zacks.com | Nektar Posts Wider Loss, Maintains View - Analyst Blog May 15 / Zacks.com |
| Pipeline Progress at Gilead - Analyst Blog May 16 / Zacks.com | Lilly Scraps Oncology Candidate - Analyst Blog May 13 / Zacks.com |
| ASCO '13 Preview: New 'Anti-PD-1' Therapies Shrink Tumors May 15 / TheStreet.com | PDL BioPharma Misses Earnings Ests - Analyst Blog May 13 / Zacks.com |
| ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Up May 15 / TheStreet.com | Narrower-than-Expected Loss at Seattle Genetics - Analyst Blog May 08 / Zacks.com |
| Previous close | 252.75 |
| Today’s open | 254.74 |
| Day’s range | 252.95 - 254.74 |
| Volume | 230 |
| Average volume (3 months) | 1,968 |
| Market cap | $177.6B |
| Dividend yield | 3.08% |
| Earnings growth (last year) | -3.44% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +1.09% |
| P/E ratio | -- |
| Price/Sales | 3.50 |
| Price/Book | 13.77 |
| No competitors data available. |
| Next reporting date | -- |
| EPS forecast (this quarter) | -- |
| Annual revenue (last year) | $48.5B |
| Annual profit (last year) | $10.2B |
| Net profit margin | 20.97% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer & Director Severin Schwan, LLD |
Chief Financial & Information Technology Officer Alan Hippe, PhD |
Corporate headquarters Basel, Basel-stadt (basle Town) |
.
